Hardman & Co Research Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven 21-Nov-2024 / 11:15 GMT/BST The issuer
EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived 21.11.2024 /
EQS-News: Pentixapharm Holding AG / Key word(s): Study First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding
EQS-News: MPH Health Care AG / Key word(s): 9 Month figures/Quarter Results EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR
Xlife Sciences AG / Key word(s): Expansion/IPO 21-Nov-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is
Hardman & Co Research Hardman & Co Investor Forum Research on Custodian Property Income REIT (CREI): Good momentum, modest risk 20-Nov-2024 / 13:55 GMT/BST The
Hardman & Co Research Hardman & Co Q&A on Duke Capital (DUKE): Equity raise and third-party capital update 20-Nov-2024 / 10:30 GMT/BST The issuer is
EQS-News: Cantourage Group SE / Key word(s): Development of Sales/Monthly Figures New Sales Record: Cantourage Group SE Reports EUR 5.5 Million in Revenue for October
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Establishes an At-the-Market (ATM) Program on Nasdaq 19.11.2024 / 22:30 CET/CEST The issuer is solely responsible for the
EQS-News: Zentiva AG / Key word(s): Mergers & Acquisitions Condition of minimum acceptance in Zentiva’s Voluntary Public Purchase Offer waived – Acceptance Period remains unchanged